The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Improving the definition of high-risk patients for tumor recurrence from clear cell renal cell carcinoma: The U-CISS classification.
 
Cedric Michel Lebacle
Research Funding - Pfizer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Ipsen
 
Nils Kroeger
No Relationships to Disclose
 
Aydin Pooli
Stock and Other Ownership Interests - Alimera Sciences; UroGen pharma
 
Sandy Liu
No Relationships to Disclose
 
Karim Chamie
Consulting or Advisory Role - AstraZeneca; Urogen pharma
Other Relationship - Altor BioScience
 
Arie S. Belldegrun
Employment - Alimera Sciences; Kronos; UroGen pharma
Leadership - Alimera Sciences; Kronos; UroGen pharma
Stock and Other Ownership Interests - Alimera Sciences; Kronos; UroGen pharma
 
Brian Shuch
No Relationships to Disclose
 
Alexandra Drakaki
Employment - Kyn therapeutics (I)
Leadership - Kyn therapeutics (I)
Stock and Other Ownership Interests - Alimera Sciences (I); UROGENE (I)
Consulting or Advisory Role - Bristol-Myers Squibb; Kyn therapeutics
Research Funding - Kite, a Gilead company
Patents, Royalties, Other Intellectual Property - 5 PATENTS AT UCLA FOR 5 POTENTIAL DRUGS (I)
Travel, Accommodations, Expenses - Lilly
 
Allan J. Pantuck
Employment - Kyn Therapeutics
Leadership - Kyn Therapeutics
Stock and Other Ownership Interests - Alimera Sciences; UroGen pharma
Honoraria - Pfizer
Consulting or Advisory Role - Pfizer